(Total Views: 577)
Posted On: 06/05/2019 11:34:22 PM
Post# of 30066
Gerald's presentation reiterated some points
Todos - mentioned in previous post, similar discussion.
Coeptis -
1. Will own roughly 50% once the transaction is complete.
2. Coeptis is working on a Capital Raise to complete the transaction
3. Coeptis will be launching their first product later this year.
4. That will fund Eltop moving forward.
5. Happy with the new CEO MODI OBOCHI there formerly from Pfizer -http://coeptispharma.com/executive-team/
Cutanogen -
Looking at very strategic transactions
Actively designing Phase 3 trial.
MANF - Spinoff as a standalone
New Insight around the Hemp space talk from last week.
1. Will enterr the space to generate cash flow
2. Looking at the space in terms of diagnostic, therapeutic and wellness
3. Would aquire synergistic assets.
He referenced "Apple" in terms of what he sees this part of the company would look like Apple's
Ecosystem, but in the Hemp space.
The Hemp Ecosystem would have value creation, data capture and then outcomes.
Todos - mentioned in previous post, similar discussion.
Coeptis -
1. Will own roughly 50% once the transaction is complete.
2. Coeptis is working on a Capital Raise to complete the transaction
3. Coeptis will be launching their first product later this year.
4. That will fund Eltop moving forward.
5. Happy with the new CEO MODI OBOCHI there formerly from Pfizer -http://coeptispharma.com/executive-team/
Cutanogen -
Looking at very strategic transactions
Actively designing Phase 3 trial.
MANF - Spinoff as a standalone
New Insight around the Hemp space talk from last week.
1. Will enterr the space to generate cash flow
2. Looking at the space in terms of diagnostic, therapeutic and wellness
3. Would aquire synergistic assets.
He referenced "Apple" in terms of what he sees this part of the company would look like Apple's
Ecosystem, but in the Hemp space.
The Hemp Ecosystem would have value creation, data capture and then outcomes.
(4)
(1)
